These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Wipe Sampling Method and Evaluation of Environmental Variables for Assessing Surface Contamination of 10 Antineoplastic Drugs by Liquid Chromatography/Tandem Mass Spectrometry. Colombo M; Jeronimo M; Astrakianakis G; Apte C; Hon CY Ann Work Expo Health; 2017 Oct; 61(8):1003-1014. PubMed ID: 29028255 [TBL] [Abstract][Full Text] [Related]
43. Antineoplastic drugs determination by HPLC-HRMS(n) to monitor occupational exposure. Dal Bello F; Santoro V; Scarpino V; Martano C; Aigotti R; Chiappa A; Davoli E; Medana C Drug Test Anal; 2016 Jul; 8(7):730-7. PubMed ID: 26041114 [TBL] [Abstract][Full Text] [Related]
44. Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Yoshida J; Koda S; Nishida S; Nakano H; Tei G; Kumagai S Ann Occup Hyg; 2013 Mar; 57(2):251-60. PubMed ID: 23002276 [TBL] [Abstract][Full Text] [Related]
45. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Connor TH; Anderson RW; Sessink PJ; Broadfield L; Power LA Am J Health Syst Pharm; 1999 Jul; 56(14):1427-32. PubMed ID: 10428450 [TBL] [Abstract][Full Text] [Related]
46. The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production. Werumeus Buning A; Geersing TH; Crul M Int J Pharm Pract; 2020 Feb; 28(1):66-74. PubMed ID: 31489970 [TBL] [Abstract][Full Text] [Related]
47. Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment. Pretty JR; Connor TH; Spasojevic I; Kurtz KS; McLaurin JL; B'Hymer C; Debord DG J Oncol Pharm Pract; 2012 Mar; 18(1):23-36. PubMed ID: 21183556 [TBL] [Abstract][Full Text] [Related]
48. Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo. Schierl R; Masini C; Groeneveld S; Fischer E; Böhlandt A; Rosini V; Paolucci D J Oncol Pharm Pract; 2016 Feb; 22(1):37-45. PubMed ID: 25227229 [TBL] [Abstract][Full Text] [Related]
49. UPLC-MS/MS method for simultaneous determination of cyclophosphamide, docetaxel, doxorubicin and 5-fluorouracil in surface samples. da Silva CB; Julio IP; Donadel GE; Martins I J Pharmacol Toxicol Methods; 2016; 82():68-73. PubMed ID: 27521053 [TBL] [Abstract][Full Text] [Related]
50. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. Clark BA; Sessink PJ J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973 [TBL] [Abstract][Full Text] [Related]
51. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers. Delafoy C; Roussy C; Hudon AF; Cirtiu CM; Caron N; Bussières JF; Tanguay C J Oncol Pharm Pract; 2023 Mar; 29(2):338-347. PubMed ID: 35018847 [TBL] [Abstract][Full Text] [Related]
52. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective Phase III. Bigelow S; Schulz H; Dobish R; Chambers CR J Oncol Pharm Pract; 2009 Sep; 15(3):157-60. PubMed ID: 19171554 [TBL] [Abstract][Full Text] [Related]
53. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. Sabatini L; Barbieri A; Tosi M; Violante FS J Mass Spectrom; 2005 May; 40(5):669-74. PubMed ID: 15739158 [TBL] [Abstract][Full Text] [Related]
54. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647 [TBL] [Abstract][Full Text] [Related]
55. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. Berruyer M; Tanguay C; Caron NJ; Lefebvre M; Bussières JF J Occup Environ Hyg; 2015; 12(2):87-94. PubMed ID: 25105559 [TBL] [Abstract][Full Text] [Related]
56. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542 [TBL] [Abstract][Full Text] [Related]
57. Development of a closed drug preparation method for oral anticancer drugs. Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970 [TBL] [Abstract][Full Text] [Related]
58. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process. Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165 [TBL] [Abstract][Full Text] [Related]
59. Biological monitoring of occupational exposure to antineoplastic drugs in hospital settings. Sabatini L; Barbieri A; Lodi V; Violante FS Med Lav; 2012; 103(5):394-401. PubMed ID: 23077799 [TBL] [Abstract][Full Text] [Related]
60. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Draicchio F; Apostoli P Rapid Commun Mass Spectrom; 1998; 12(20):1485-93. PubMed ID: 9796535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]